(+)-CIS TETRAHYDROCANNABINOL ((+)-CIS-THC) FOR USE AS A MEDICAMENT
The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (−)-trans- tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (+)-cis tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (−)-trans-THC. The cannabinoid (+)-cis-THC has been found to occur in low concentrations in particular cannabis plant strains which have been bred to produce cannabidiol (CBD) as the dominant cannabinoid. Furthermore, the cannabinoid can be produced by synthetic means.
1 . (+)-cis tetrahydrocannabinol ((+)-cis-THC) for use as a medicament.
2 . (+)-cis-THC for use according to claim 1 , wherein the (+)-cis-THC is in the form of a plant extract.
3 . (+)-cis-THC for use according to claim 2 , wherein the (+)-cis-THC is in the form of a highly purified plant extract.
4 . (+)-cis-THC for use according to claim 3 , wherein the (+)-cis-THC comprises at least 80% (w/w) (+)-cis-THC.
5 . (+)-cis-THC for use according to claim 3 , wherein the (+)-cis-THC comprises at least 95% (w/w) (+)-cis-THC.
6 . (+)-cis-THC for use according to claim 1 , wherein the (+)-cis-THC is in the form of a synthetic compound.
7 . (+)-cis-THC for use according to any of the preceding claims, wherein the dose of (+)-cis-THC is greater than 100 mg/kg/day.
8 . (+)-cis-THC for use according to any of the preceding claims, wherein the dose of (+)-cis-THC is less than 100 mg/kg/day.
9 . A composition for use as a medicament comprising (+)-cis tetrahydrocannabinol ((+)-cis-THC) and one or more pharmaceutically acceptable excipients.
10 . (+)-cis tetrahydrocannabinol ((+)-cis-THC) for use in the treatment of pain.
11 . A process for the preparation of (+)-cis tetrahydrocannabinol ((+)-cis-THC).